Malignant ovarian germ cell tumor in King Chulalongkorn Memorial Hospital.
Article
Dans Anglais
| IMSEAR
| ID: sea-42758
ABSTRACT
OBJECTIVES:
To determine the frequency, characteristics, treatment and outcome of patients with malignant ovarian germ cell tumor (MOGCT) in King Chulalongkorn Memorial Hospital during the period January 1992 - December 2000. STUDYDESIGN:
Retrospective descriptive study MATERIAL ANDMETHOD:
All patients with malignant ovarian germ cell tumor in King Chulalongkorn Memorial Hospital during the period January 1992 - December 2000 were analyzed by the characteristics of patients, treatment and outcome.RESULTS:
Sixty-six patients with MOGCT were demonstrated in that period with a mean age of 22.6 years old. Most of the patients were nulliparous and premenopausal status. Primary surgery was done in all patients. Forty-two patients (63.6%) received conservative surgery. Eight patients received no adjuvant treatment after surgery due to stage 1A dysgerminoma and immature teratoma stage I grade I. Fifty-six patients received chemotherapy for adjuvant treatment. VAC regimen was given in 27 cases (40.9%) and PVB regimen was given in 25 cases (37.9%). Salvage therapy in the patients with persistent and recurrent disease was treated in 9 patients, who received a platinum-base of regimen. Two-year survival was 88% with the median time to follow up 24 months. Overall five-year survival in the present study was 85%.CONCLUSION:
MOGCT in King Chulalongkorn Memorial Hospital had clinical characteristics similar to other studies in malignant ovarian germ cell tumor Treatment by VAC regimen still has benefit in selected group.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Tumeurs de l'ovaire
/
Thaïlande
/
Hôpitaux urbains
/
Femelle
/
Humains
/
Analyse de survie
/
Enfant
/
Incidence
/
Études rétrospectives
/
Adolescent
Type d'étude:
Etude d'incidence
/
Étude observationnelle
/
Étude pronostique
Pays comme sujet:
Asie
langue:
Anglais
Année:
2005
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS